Genentech, a subsidiary of Roche, just established a deal today with a biotech by the name of Repertoire Immune Medicines to use its DECODE platform technology to develop T-cell targeted immune medicines for the treatment of patients with autoimmune...
Just today, Bristol-Myers Squibb announced that it had failed to achieve the primary endpoint of its phase 3 ARISE trial, which was evaluating the use of COBENFY as an adjunctive treatment with atypical antipsychotics in adults with inadequately controlled...
Earlier this month, Tempest Therapeutics announced that it would explore strategic alternatives for its oncology pipeline of assets. Specifically, it has a phase 3 ready drug in its pipeline known as Amezalpat (TPST-1120), which had already been studies in...
Eli Lilly just can't seem to stop with the continuous wins in the clinic because just today it announced that it had achieved positive results from its phase 3 ACHIEVE-1 study. This late-stage trial was evaluating the safety and...
Things didn't go very well today for Sanofi, because it announced that its phase 2 TIDE-Asthma study failed to achieve the primary endpoint of annualized exacerbation rate at week 48, which was not met with statistical significance. Any type...
Things didn't go as planned with Mural Oncology in terms of another shot on goal for its lead IL-2 candidate, Nemvaleukin alfa. That's because just today it announced that it had failed to achieve desired efficacy in two cohorts...
